#242 — Psychedelics and the Self

Episode Summary

Executive Summary: Sam Harris interviews James Fadiman about psychedelic safety, preparation, and dosing, then moves into microdosing and its reported effects. Fadiman stresses set, setting, intention, and a trustworthy guide for high-dose work, distinguishes psychedelic categories and dose ranges, and argues that microdosing is subtle, individualized, and often more functional than intoxicating. The episode also frames psychedelics as tools for insight, not recreation.

Main Topics: Fadiman’s background and early psychedelic research (Priority: 5/5): Fadiman recounts how Richard Alpert introduced him to psychedelics, his Stanford graduate work, and his early clinical research before government shutdowns halted the field. Who should take psychedelics and who should not (Priority: 5/5): The discussion emphasizes individual caution, especially for people with psychosis, schizophrenia, bipolar disorder, or serious mental illness, while noting the evidence base is less definitive than commonly assumed. Set, setting, situation, and the role of a guide (Priority: 5/5): Fadiman argues that preparation, physical environment, mental intention, and a skilled, caring sitter or guide are central to reducing negative experiences and improving outcomes. Dose ranges and phenomenology of high-dose psychedelics (Priority: 5/5): They map approximate LSD and psilocybin dose ranges to effects from mild perceptual changes to psychotherapeutic work and mystical/unitive experiences. Comparing LSD, psilocybin, MDMA, and DMT (Priority: 4/5): The conversation distinguishes LSD from psilocybin in tone and duration, explains why MDMA is psychologically different from classic psychedelics, and briefly addresses DMT and ayahuasca as different doors into altered consciousness. Microdosing as enhancement rather than intoxication (Priority: 5/5): Fadiman defines microdosing as sub-psychedelic, repeated dosing intended to improve mood, creativity, productivity, and social functioning without disrupting ordinary life. Psychedelics, identity, and the multiple self (Priority: 3/5): The episode closes by previewing Fadiman’s work on healthy multiplicity and the idea that the self is not a single unified entity, which may support compassion and acceptance.

Key Arguments: Psychedelics are physically relatively safe, but they can still produce psychologically difficult or destabilizing experiences if used without preparation and understanding. The question of whether someone should take psychedelics cannot be answered abstractly; personal hesitation is itself a meaningful warning signal. High-dose experiences benefit from a guide/sitter who is calm, caring, and experienced enough to help reframe panic or ego dissolution. Set, setting, and life situation strongly shape outcomes; even a good environment cannot fully offset severe life stress. Dosing is individual, not purely weight-based or standardized; the right dose depends on the person, the day, and the intention. Psilocybin is often experienced as gentler and shorter-acting than LSD, while LSD is described as more cold/powerful and longer-lasting. MDMA is not a classic psychedelic because it does not typically take people beyond the self; instead, it can help process trauma within a safer inner space. Microdosing should not feel like a high; its value is subtle improvements in mood, focus, creativity, and functioning over repeated use. Microdosing may have both benefits and downsides: it can brighten attention and performance but may also amplify anxiety in susceptible people.

Data Points: Government shutdown of early psychedelic research: Closed in the early 1960s after dissertation work on psychedelic therapy - Fadiman describes his Stanford-era research being halted by the government before the field could continue Initial LSD microdose used in Fadiman’s early work: 10 micrograms - Presented as an early working microdose for LSD that produced functional benefits without disrupting daily life Psilocybin microdose range: 0.2 to 0.5 grams - Fadiman’s early microdosing reports for mushrooms before people self-corrected to lower amounts Self-corrected mushroom microdose: About 0.1 gram - Participants often reduced dose after finding the initial amount too strong Low-dose LSD perceptual threshold: Around 25 micrograms - Described as a very mild psychedelic effect range Museum/concert dose: Around 50 micrograms - Linked to a visually enhanced but relatively manageable LSD experience Scientific-research dose: Around 100 micrograms - Fadiman describes this as enabling hard-nosed scientific research Psychotherapeutic dose range: 100 to 200 micrograms - At this range, therapy can still occur with communication intact and meaningful material accessible Mystical/transcendent dose range: Above 200 up to 400 micrograms - Associated with unity experiences, ego dissolution, and deep identity shifts LSD duration: 8 to 12 hours - Used as a practical reason many studies prefer psilocybin Psilocybin duration: 4 to 6 hours - Cited as shorter and more practical for research sessions High-dose afterglow: 4 to 6 weeks - Fadiman notes longer-lasting positive effects after high-dose psychedelic sessions Microdosing schedule: 1 day on, 2 days off over a month - A common regimen in Fadiman’s reports, roughly 10 doses per month Citizen-scale psychedelic exposure: 30 million people - Fadiman says this many people have tried high-dose psychedelics or LSD in the U.S. since prohibition Death count discussed: No deaths reported - Fadiman claims there have been no deaths from the high-dose psychedelic use he referenced

Pivotal Quotes: "If you feel there's a reason you shouldn't take a psychedelic, you have to listen to that." — James Fadiman: On who should not take psychedelics and the importance of personal caution "Set and setting and situation" — James Fadiman: His preferred framing for preparation, environment, and life context shaping psychedelic outcomes "I think that psychedelics are incredibly sensitive to set or your mental attitude and setting, the literally physical situation you're in, and that includes the other people who are around." — James Fadiman: On why preparation and environment are central to safe and productive experiences

Implications: The episode treats psychedelics as serious instruments for psychological work, not casual recreation. For listeners and the field, the big takeaways are careful screening, trusted supervision, and individualized dosing; microdosing remains promising but requires more rigorous evidence.